非布司他疗效如何呢？

Febuxostat (Febuxostat) is a xanthine oxidase (XO) inhibitor approved by the US FDA in 2009. It is suitable for the long-term treatment of hyperuricemia with gout symptoms. Not recommended for the treatment of asymptomatic hyperuricemia. It has been approved for marketing in my country.

For many newly diagnosed patients who are taking medication, they still don’t know much about febuxostat. Today we will take a look at the efficacy of febuxostat, which everyone is most concerned about.

The molybdopterin center is an extremely critical site in the process of generating uric acid from xanthine. Febuxostat (Febuxostat) can treat gout by tightly binding to the central active site of XO molybdopterin, so that the oxidized or reduced molybdenum cofactor remains in an isolated state, thereby inhibiting the collection of XO and substrates, reducing the formation of uric acid, and lowering the level of uric acid in the blood.

Different from allopurinol, febuxostat has a non-purine analogue structure, so it selectively binds to XO and does not interact with other enzymes in the metabolism of purine and pyrimidine (such as purine nucleoside phosphorylase, etc.), nor does it affect the metabolism of pyrimidine and purine. Allopurinol is a purine analogue, which can affect the activity of other enzymes involved in purine and pyrimidine metabolism in the body and is prone to some adverse reactions. Febuxostat can avoid these possible adverse reactions.

Judging from official clinical trials, the effectiveness of febuxostat (Febuxostat) in the general population is about 70%, which is much higher than that of allopurinol. And compared to placebo, there was a clear difference. Clinical trial data on more than 3,000 people show that febuxostat can effectively reduce uric acid in the blood to 360 μmol/L after taking the drug for six months.

In summary, febuxostat (Febuxostat) has played a positive and effective role in the trial of treating gout patients, bringing a new treatment option to gout patients at home and abroad.